The Playground

    Quote from Bob#2

    If data says 100 people were vaccinated and 10 died that would be 10%.

    But if 70% of the 100 were protected by previous Covid infection and not really by the vaccines, then it would leave 30 people vaccinated (not previously infected) with 10 deaths and that is 30% death rate.

    Exactly this is the reality. To hide this fact Pfizer decided to vaccinate the control group of the phase III study. So basically the use/distribution of the Pfizer "vaccine" is illegal since July 2021 as there is no phase III study...


    With Omicron the game is definitely over. Here in ZH not a single patient has been admitted to ICU because of Omicron. All came in with Stroke, Accident and have been detected on entry...The same has been reported from RSA. Only immune compromised are at risk as of any other virus....


    How the vaccine terror mafia silently kills people: https://www.bbc.com/news/world-us-canada-60132765


    How and why the DE,FR,AU,... Nazi governments still promote CoV-19 "vaccination" as a solution has one simple answer. Money. RNA "vaccinated" get 4x more often CoV-19 and even boosters give you no protection as Israel data shows. Please remember the huge faking effect of including all recovered in the vaccinated subset. As studies in RSA did show, only the "recovered and vaccinated" are protected from Omicron! The gene therapy alone fails!

    Quote from Fm1

    Pfizer announced on Tuesday that they and partner BioNTech are starting trials of an Omicron-based booster.

    This will be a death row trial. Please stay off if you got a first RNA gene therapy. Such a second shot will lead to RNA x RNA ADE with unkown outcome. I expect very high rates of all odd effects seen so far.

    Covid-⁠19 Schweiz | Coronavirus | Dashboard
    Covid-⁠19 Pandemie Schweiz und Liechtenstein: Fallzahlen, Virusvarianten, Hospitalisationen, Re-⁠Wert, Spitalkapazitäten, internationale Lage, Zahlen zu Tests,…
    www.covid19.admin.ch

    We have new record numbers of > 40'000 cases/day with a positive rate of > 40% what means 1/4 of Switzerland is currently having it...but most do not know it...


    Switzerland:: Despite more testing we do not manage to fill the hospital ICU's. https://www.covid19.admin.ch/de/hosp-capacity/icu

    May be we have more recovered and factually Pfizer crap is < 1/3 of the gene therapy (vaccine) story...

    Big pharma ignores reports of myocarditis!


    Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine


    Yahooist Teil der Yahoo Markenfamilie


    When I Told Pfizer About Incidents of Myocarditis They Refused to Believe Me for Four Months’

    Israel had the potential to be the first country in the world to detect side effects of the coronavirus vaccines. And it did detect two, almost by accident. But its disregard for more minor effects cost it public trust

    ‘When I told Pfizer about incidents of myocarditis they refused to believe me for four months’
    ***
    www.haaretz.com

    Quote from Fm1

    He is speaking out now because he was ignored by big pharma for months.

    Not ignored... The FM/R/B mafia rules most countries. E.g. in Germany only a criminal can become "Kanzler"...or Turkey/Russia,...leader...


    Let the data speak :: https://healthimpactnews.com/2…mental-covid-19-vaccines/


    USA:: Experimental CoV-19 gene therapy (C19 vaccines) did kill > 2x more people within 1 year than all vaccines before in 32 years

    Omicron's new variant cousin, BA.2, has arrived in the US. But don't panic yet, experts say.
    eu.cincinnati.com


    Yes, a new variant of omicron is spreading on at least four continents. But, no, it shouldn't be a cause for panic, Massachusetts scientists said Tuesday.

    Unlike two years ago when everyone was first learning about COVID-19, there are now many tools to combat the disease, and, like its cousin, omicron BA.2 is expected to remain relatively mild.

    "I don't think it's going to cause the degree of chaos and disruption, morbidity and mortality that BA.1 did," said Dr. Jacob Lemieux, an infectious disease specialist at Massachusetts General Hospital in Boston. "I'm cautiously optimistic that we're going to continue to move to a better place and, hopefully, one where each new variant on the horizon isn't news."

    'STAYING VIGILANT AGAINST THE VIRUS': Pfizer and BioNTech announce plans to test omicron-specific COVID-19 vaccine in adult trials

    While COVID-19 cases have begun to decline in places like Massachusetts, where omicron hit hard late last year, cases of BA.2 are on the rise in the Philippines, India, Denmark and South Africa, Lemieux said. Cases have been reported in the United States, too – so far in California, New Mexico, Texas and Washington state.

    It's not clear yet whether BA.2 is pushing out the original omicron variant, now referred to as BA.1, he said.

    University of Minnesota COVID-OUT Study Ships Ivermectin to Patient’s Homes Next Day—Study Nears Completion & Still Seek Participants


    University of Minnesota COVID-OUT Study Ships Ivermectin to Patient’s Homes Next Day—Study Nears Completion & Still Seek Participants
    The COVID-OUT study has been profiled on TrialSite as one of the largest drug repurposing studies in the United States. Sponsored by the University of
    trialsitenews.com


    The COVID-OUT study has been profiled on TrialSite as one of the largest drug repurposing studies in the United States. Sponsored by the University of Minnesota in partnership with UnitedHealthcare (Optum), recent media entries suggest the clinical investigators close in on the end of the clinical trial testing ivermectin and two other repurposed drugs including fluvoxamine within a month. The study is led by principal investigator Carolyn Bramante, MD, and David Boulware whom TrialSite recently interviewed.


    Announcing this study last year, TrialSite reported that in addition to support from UnitedHealthcare’s OptumLabs, a division of one of Americas’ largest health insurers, more support came from the Parsemus Foundation, the Rainwater Charitable Foundation, and Fast Grants.


    The Study

    This study evaluates if existing repurposed therapies can treat COVID-19, including the antidepressant fluvoxamine and the diabetes treatment drug, metformin. However, the study is probably most known for its inclusion of ivermectin, the antiparasitic drug that many people not only in the United States but also in other parts of the world have used off-label to treat COVID-19. To date, ivermectin is only approved in America for antiparasitic use.


    Recently covered in the Minneapolis Star Tribune, the study lead Dr. Bramante went on the record that the study results just might offer some parameters for physicians who seek to use highly available, low cost repurposed drugs. Bramante declared, “Sooner would have been better, but I’m really proud of my team. We will be done very quickly.”



    This University of Minnesota-led study targeted 1,100 COVID-19 patients for enrollment to be treated with fluvoxamine and ivermectin alone or in combination with metformin, or a placebo option as a comparator.


    The patients are given the orally administered drug for 14 days and the hope is that the regimen will help reduce hospitalization rates while helping the patients maintain healthy blood oxygen levels, reports Jeremy Olson from the Star Tribune.


    Importantly, over 70 studies from around the world offer some positive data, yet the medical establishment in places like America has been resistant to accept the drug. A comprehensive list of those studies can be found here.


    Ivermectin Abroad & Home

    TrialSite has reported extensively on the potentially positive contribution the drug has made to fighting COVID-19, such as in Uttar Pradesh, India. In the United States during the summer of 2020, Dr. Jean-Jacques Rajter and his wife Juliana Cepelowicz-Rajter completed a successful real-world case series at Broward County Health. The results of that study, known as ICON, were published in the journal, Chest.


    Around the world ivermectin is promoted as a drug to be used during the early onset of the SARS-CoV-2 infection, acknowledged Dr. Bramante in the recent Star Tribune piece.


    Overnight Shipping to Patients

    When TrialSite interviewed Bramante during the summer of 2021, she reported that University of Minnesota researchers ship the drug to patients at their homes via an overnight shipping depot in a bid to ensure the study drug makes it to those participants with COVID-19 who enroll in less than a day.


    Recently, TrialSite interviewed the University of Minnesota’s Dr. David Boulware who oversees COVID-OUT as well as other studies. That interview can be seen on the TrialSite YouTube channel.

    Dr. David Boulware Discusses Early Treatment Trial for COVID-19
    Dr. Boulware is an infectious disease expert and researcher at the University of Minnesota. He is one of the lead investigators of the COVID-OUT clinical trial…
    rumble.com


    Call to Action: For those individuals who become infected with SARS-CoV-2, the virus behind COVID-19, and seek an ivermectin-based study, reach out to the COVID-Out study team to consider participation. Numerous other organizations are participating in this important study including:


    Emory University School of Medicine

    Olive View UCLA Medical Center

    University of Colorado, Anschutz Medical Campus

    Hennepin Health Care

    Northwestern Medicine

    M Health Fairview

    For those that want to participate visit the COVID-OUT website.


    Lead Research/Investigators

    Carolyn Bramante, MD, MPH


    David Boulware, MD, MPH


    University of Minnesota ivermectin trial nearing completion
    Proof of effectiveness would give doctors outpatient COVID-19 therapies amid limited antiviral and antibody supplies.
    www.startribune.com

    Hybrid immunity provides greater levels of immunity.


    A new study finds that two forms of immunity—breakthrough infections following vaccination or natural infection followed by vaccination—provide roughly equal levels of enhanced immune protection.


    The new study found that it doesn't matter whether someone gets a breakthrough infection or gets vaccinated after a natural infection. In both cases, the immune response measured in blood serum revealed antibodies that were equally more abundant and more potent—at least 10 times more potent—than immunity generated by vaccination alone.


    "Immunity from natural infection alone is variable. Some people produce a strong response and others do not," said Curlin, associate professor of medicine (infectious diseases) in the OHSU School of Medicine and director of OHSU Occupational Health. "But vaccination combined with immunity from infection almost always provides very strong responses.

    Quote from Bob#2

    I think you misunderstand him... He is stating that 70% of the population if protected by previous infection that is being attributed to the vaccine.... I.E.. they had Covid and natural immunity is protecting them, not the vaccine but the information being presented is that it is the vaccine that is protecting them. I think he is stating that those that perish are only vaccinated and not previously infected. So if the total number is reduced by 70% but the deaths stay the same, then the rate of death for vaccinated is much higher.

    The number of deaths, over time, depends on the infection rate, which is highly variable.


    All we can do is look at the relative mortality between those vaccinated and unvaccinated - for that - 70% being protected does not alter the determination.


    Since the death rate in unvaccinated is 3X the death rate in vaccinated, and that 70% protected fraction would have the same effect on rate for both, his argument does not make sense?


    I'm sort of used to that on this thread.


    THH

    Here you are FM1


    Dror has co-authored a decent paper in nature on vaccine-induced myocarditis. And no-one has ignored it - it was put on the watch list for mRNA vaccines very early on and is still a matter of concern.


    The results are “in sync with what we have seen before”, says Fiona Russell, a paediatrician and infectious-diseases epidemiologist at the University of Melbourne in Australia.

    A study3 of US military personnel by Leslie Cooper, a cardiologist at Mayo Clinic in Jacksonville, Florida, and his colleagues, published in June, identified 23 cases of myocarditis in men aged 20–51 who had received an mRNA vaccine, working out to 8 cases per 100,000. All of the men recovered. The same month, the US Centers for Disease Control and Prevention (CDC) reported that it had identified 5 cases out of 100,000 in men aged 18–24, rising to 6 cases per 100,000 in male adolescents aged 12–17. Most people who developed myocarditis recovered quickly, according to the CDC.



    That is the medicine. There is then the politics, and strategy, of who you vaccinate when balancing all the risks.


    Heart-inflammation risk from Pfizer COVID vaccine is very low
    Two studies from Israel quantify the risk of myocarditis following the Pfizer–BioNTech shot, with one suggesting the chance of developing the condition is…
    www.nature.com

    That is great news and totally blows out of the water this idea that vaccination does something nasty to the immune system (ADE etc).


    Of course ADE exists, but not enough in this case to offset the benefits of vaccination. This shows that vaccination before surviving COVID is by far the safest way to go.

    Quote from THHuxleynew

    Since the death rate in unvaccinated is 3X the death rate in vaccinated, and that 70% protected fraction would have the same effect on rate for both, his argument does not make sense?

    You exactly got it: Your argument does not make sense. A gray paint for a tiger does not make it an elephant... But this is what Big Pharma cheaters do...


    Only fools believe such fake statistics.


    To many FM/R/B criminals live on this planet....

    Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine


    Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case–Control Study: Annals of Internal Medicine: Vol 0, No 0
    Background: Case reports of carditis after BNT162b2 vaccination are accruing worldwide. Objective: To examine the association of BNT162b2 and CoronaVac…
    www.acpjournals.org


    Abstract

    Background:

    Case reports of carditis after BNT162b2 vaccination are accruing worldwide.


    Objective:

    To examine the association of BNT162b2 and CoronaVac (Sinovac) vaccination with carditis.


    Design:

    Case–control study with hospital control participants.


    Setting:

    Territory-wide, public health care database with linkage to population-based vaccination records in Hong Kong.


    Patients:

    Inpatients aged 12 years or older first diagnosed with carditis were selected as case patients. All other hospitalized patients without carditis were treated as control participants. Ten control participants were randomly matched with each case patient by age, sex, and admission date.


    Intervention:

    Vaccination with BNT162b2 or CoronaVac.


    Measurements:

    Incident diagnosis of carditis based on the International Classification of Diseases, Ninth Revision, and elevated troponin levels.


    Results:

    A total of 160 case patients and 1533 control participants were included. Incidence of carditis per 100 000 doses of CoronaVac and BNT162b2 administered was estimated to be 0.31 (95% CI, 0.13 to 0.66) and 0.57 (CI, 0.36 to 0.90), respectively. Multivariable analyses showed that recipients of the BNT162b2 vaccine had higher odds of carditis (adjusted odds ratio [OR], 3.57 [CI, 1.93 to 6.60]) than unvaccinated persons. Stratified by sex, the OR was 4.68 (CI, 2.25 to 9.71) for males and 2.22 (CI, 0.57 to 8.69) for females receiving the BNT162b2 vaccine. The ORs for adults and adolescents receiving the BNT162b2 vaccine were 2.41 (CI, 1.18 to 4.90) and 13.79 (CI, 2.86 to 110.38), respectively. Subanalysis showed an OR of 9.29 (CI, 3.94 to 21.91) for myocarditis and 1.06 (CI, 0.35 to 3.22) for pericarditis associated with BNT162b2. The risk was mainly seen after the second dose of BNT162b2 rather than the first. No association between CoronaVac and carditis with a magnitude similar to that for BNT162b2 was seen.


    Limitation:

    Limited sample size, absence of electrocardiography and other clinical investigative data, and unrecorded overseas vaccination exposure.


    Conclusion:

    Despite a low absolute risk, there is an increased risk for carditis associated with BNT162b2 vaccination. This elevated risk should be weighed against the benefits of vaccination.


    Primary Funding Source:

    Health and Medical Research Fund.

    My dear old father in law passed beyond the veil last night around 8pm, when care staff found him at rest in his bed a few hours after supper. He had experienced a good last day. His appetite had returned after the previous three days when he hadn't been eating or drinking much, a puzzling thing since he was always a good eater. Then a nurse had an aha moment and informed my wife that he had got his fourth vaccine about four days ago, and that may have explained why he wasn't feeling well the next few days. Well, he rallied on the fourth day, and then unexpectedly left us at the age of 94. Cause of death on the death certificate : Dementia. See you on the other side Grandpa. Here's is a cropped picture of him while standing next to three of his siblings about five years ago in London Ontario.


    Why can vaccines (during silent phases) kill the elderly at a higher rate than CoV-19??


    Here the CoV-19 mortality for Switzerland :: https://www.covid19.admin.ch/d…iologic/death?time=phase4


    Here the excess mortality for Switzerland:: https://www.experimental.bfs.a…vative-methoden/momo.html


    You can clearly see that onset of excess mortality happened during the booster phase (start July,August - very mild this year!) and is not related to a CoV-19 wave...So in September.


    The CoV-19 situation in September has been the same as in April where the excess mortality was at the lower end.

Subscribe to our newsletter

It's sent once a month, you can unsubscribe at anytime!

View archive of previous newsletters

* indicates required

Your email address will be used to send you email newsletters only. See our Privacy Policy for more information.

Our Partners

Supporting researchers for over 20 years
Want to Advertise or Sponsor LENR Forum?
CLICK HERE to contact us.